JPWO2022226005A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022226005A5 JPWO2022226005A5 JP2023564448A JP2023564448A JPWO2022226005A5 JP WO2022226005 A5 JPWO2022226005 A5 JP WO2022226005A5 JP 2023564448 A JP2023564448 A JP 2023564448A JP 2023564448 A JP2023564448 A JP 2023564448A JP WO2022226005 A5 JPWO2022226005 A5 JP WO2022226005A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- amino acid
- cell
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 241
- 108010025815 Kanamycin Kinase Proteins 0.000 claims description 130
- 150000007523 nucleic acids Chemical group 0.000 claims description 100
- 238000006467 substitution reaction Methods 0.000 claims description 90
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 76
- 125000000539 amino acid group Chemical group 0.000 claims description 72
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- 210000004962 mammalian cell Anatomy 0.000 claims description 61
- 235000018102 proteins Nutrition 0.000 claims description 57
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 235000001014 amino acid Nutrition 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 45
- 108700019146 Transgenes Proteins 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 239000000758 substrate Substances 0.000 claims description 29
- 102100034349 Integrase Human genes 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 108010067390 Viral Proteins Proteins 0.000 claims description 21
- 108091027963 non-coding RNA Proteins 0.000 claims description 21
- 102000042567 non-coding RNA Human genes 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000001177 retroviral effect Effects 0.000 claims description 16
- 101710091045 Envelope protein Proteins 0.000 claims description 15
- 101710188315 Protein X Proteins 0.000 claims description 15
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 15
- 108020004566 Transfer RNA Proteins 0.000 claims description 15
- 229930027917 kanamycin Natural products 0.000 claims description 15
- 229960000318 kanamycin Drugs 0.000 claims description 15
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 15
- 229930182823 kanamycin A Natural products 0.000 claims description 15
- 229930182817 methionine Natural products 0.000 claims description 15
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 15
- 239000002679 microRNA Substances 0.000 claims description 15
- 239000004055 small Interfering RNA Substances 0.000 claims description 15
- 108091033409 CRISPR Proteins 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 14
- 108020005004 Guide RNA Proteins 0.000 claims description 13
- 108090000565 Capsid Proteins Proteins 0.000 claims description 12
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 108020005544 Antisense RNA Proteins 0.000 claims description 11
- 108090000994 Catalytic RNA Proteins 0.000 claims description 11
- 102000053642 Catalytic RNA Human genes 0.000 claims description 11
- 101710163270 Nuclease Proteins 0.000 claims description 11
- 239000003184 complementary RNA Substances 0.000 claims description 11
- 108091070501 miRNA Proteins 0.000 claims description 11
- 108020004418 ribosomal RNA Proteins 0.000 claims description 11
- 108091092562 ribozyme Proteins 0.000 claims description 11
- 102200111182 rs35520672 Human genes 0.000 claims description 10
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 101710177291 Gag polyprotein Proteins 0.000 claims description 8
- 101710125418 Major capsid protein Proteins 0.000 claims description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 229930193140 Neomycin Natural products 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 229960004927 neomycin Drugs 0.000 claims description 7
- 210000005253 yeast cell Anatomy 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 108091092724 Noncoding DNA Proteins 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 101150059079 EBNA1 gene Proteins 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000002759 chromosomal effect Effects 0.000 claims description 4
- 230000005757 colony formation Effects 0.000 claims description 4
- 238000010293 colony formation assay Methods 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000010354 integration Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 108700005077 Viral Genes Proteins 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 241000701447 unidentified baculovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177749P | 2021-04-21 | 2021-04-21 | |
| US202163177767P | 2021-04-21 | 2021-04-21 | |
| US202163177759P | 2021-04-21 | 2021-04-21 | |
| US202163177744P | 2021-04-21 | 2021-04-21 | |
| US202163177746P | 2021-04-21 | 2021-04-21 | |
| US202163177753P | 2021-04-21 | 2021-04-21 | |
| US202163177764P | 2021-04-21 | 2021-04-21 | |
| US202163177739P | 2021-04-21 | 2021-04-21 | |
| US63/177,739 | 2021-04-21 | ||
| US63/177,749 | 2021-04-21 | ||
| US63/177,746 | 2021-04-21 | ||
| US63/177,759 | 2021-04-21 | ||
| US63/177,767 | 2021-04-21 | ||
| US63/177,764 | 2021-04-21 | ||
| US63/177,753 | 2021-04-21 | ||
| US63/177,744 | 2021-04-21 | ||
| PCT/US2022/025452 WO2022226005A1 (en) | 2021-04-21 | 2022-04-20 | Materials and methods for improved phosphotransferases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516153A JP2024516153A (ja) | 2024-04-12 |
| JPWO2022226005A5 true JPWO2022226005A5 (https=) | 2025-04-25 |
| JP2024516153A5 JP2024516153A5 (https=) | 2025-04-25 |
Family
ID=83722653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564448A Pending JP2024516153A (ja) | 2021-04-21 | 2022-04-20 | 改良されたホスホトランスフェラーゼのための材料及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240191215A1 (https=) |
| EP (1) | EP4326747A4 (https=) |
| JP (1) | JP2024516153A (https=) |
| KR (1) | KR20230173159A (https=) |
| AU (1) | AU2022261882A1 (https=) |
| BR (1) | BR112023021960A2 (https=) |
| CA (1) | CA3217224A1 (https=) |
| IL (1) | IL307870A (https=) |
| MX (1) | MX2023012514A (https=) |
| TW (1) | TW202305127A (https=) |
| WO (1) | WO2022226005A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344886B2 (en) * | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
| KR101149777B1 (ko) * | 2002-11-29 | 2012-06-11 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법 |
| US20080124760A1 (en) * | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| EP1975228A1 (en) * | 2007-03-28 | 2008-10-01 | Fachhochschule Mannheim | Polynucleotides for enhancing expression of a polynucleotide of interest |
| AU2011342162B2 (en) * | 2010-12-15 | 2017-04-20 | Kyowa Kirin Co., Ltd. | Method for producing proteins |
| US11389531B2 (en) * | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
-
2022
- 2022-04-20 CA CA3217224A patent/CA3217224A1/en active Pending
- 2022-04-20 US US18/287,742 patent/US20240191215A1/en active Pending
- 2022-04-20 MX MX2023012514A patent/MX2023012514A/es unknown
- 2022-04-20 IL IL307870A patent/IL307870A/en unknown
- 2022-04-20 AU AU2022261882A patent/AU2022261882A1/en not_active Abandoned
- 2022-04-20 WO PCT/US2022/025452 patent/WO2022226005A1/en not_active Ceased
- 2022-04-20 BR BR112023021960A patent/BR112023021960A2/pt not_active Application Discontinuation
- 2022-04-20 JP JP2023564448A patent/JP2024516153A/ja active Pending
- 2022-04-20 EP EP22792366.1A patent/EP4326747A4/en active Pending
- 2022-04-20 KR KR1020237039725A patent/KR20230173159A/ko active Pending
- 2022-04-20 TW TW111114949A patent/TW202305127A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7520719B2 (ja) | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター | |
| CA3201392A1 (en) | Aav vectors for gene editing | |
| JP7833134B2 (ja) | 細菌宿主株 | |
| JP2021078516A (ja) | 細胞を再プログラム化するための精製された修飾ｒｎａを含むｒｎａ調製物 | |
| JP2023513303A (ja) | レンチウイルスベクターの製造 | |
| JP2025148329A (ja) | レンチウイルスベクターの製造方法および構築物 | |
| CA3253302A1 (en) | CELL COMPOSITIONS AND ENGINEERING METHODS | |
| WO2013080934A1 (ja) | ヒト遺伝子由来プロモーター | |
| JP2020508693A (ja) | Ｃ２ｃ１エンドヌクレアーゼを含むゲノム編集用組成物およびこれを用いたゲノム編集方法 | |
| JPWO2022226005A5 (https=) | ||
| RU2023129727A (ru) | Материалы и способы для усовершенствованных фосфоттрансфераз | |
| CN117126855A (zh) | 一种构建Igf2bp1基因敲除小鼠胚胎干细胞系的方法 | |
| KR102638799B1 (ko) | CRISPR/Cas12f1(Cas14a1) system 효율화를 위한 engineered guide RNA 및 이의 용도 | |
| KR20230121569A (ko) | 상동지정복구를 위한 TaRGET 시스템 및 이를 이용한 유전자 편집 방법 | |
| WO2022006745A1 (en) | Guide rna for hsv-1 gene editing and method thereof | |
| CN115044583A (zh) | 用于基因编辑的rna框架和基因编辑方法 | |
| Sowińska et al. | Potential limitations of the" Sleeping Beauty" transposon use in gene expression studies | |
| WO2021163515A1 (en) | Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells | |
| TWI867731B (zh) | 新的基因組安全港及其用途 | |
| WO2021002412A1 (ja) | 核酸封入ａａｖ中空粒子の製造方法 | |
| US20250270509A1 (en) | Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts | |
| HK40129088A (zh) | 产生改进的病毒和非病毒纳米质粒载体 | |
| US9890392B2 (en) | Method for preparing specific cells of human-derived cells | |
| WO2025255168A2 (en) | Modified cas12 guides and uses thereof | |
| JP2022554417A (ja) | ポリオーマｊｃ感染の阻害剤としてのｃｒｉｓｐｒ／ｃａｓ９システム |